Publications by authors named "Visca D"

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.

Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.

View Article and Find Full Text PDF

Introduction: Asthma is a chronic inflammatory respiratory disease often associated with comorbidities. Among cardiovascular comorbidities, arterial hypertension seems to create an additional health burden in asthmatics. However, evidence on this relationship is lacking.

View Article and Find Full Text PDF
Article Synopsis
  • - Mycobacterium chimaera is a non-tuberculous mycobacterium within the Mycobacterium avium complex (MAC) and is linked to infections after cardiac surgery due to heater-cooler units.
  • - Although it is considered less virulent than other MAC species like M. avium and M. intracellulare, M. chimaera has been reported to cause lung infections, especially in patients with chronic conditions.
  • - The text presents a specific case from Italy involving a patient with newly diagnosed chronic obstructive pulmonary disease (COPD) who contracted an infection from M. chimaera.
View Article and Find Full Text PDF
Article Synopsis
  • - Benralizumab effectively manages severe eosinophilic asthma (SEA), showing a significant 89% reduction in exacerbation rates and a 440 mL increase in forced expiratory volume (FEV) over 36 months in a study of 108 Italian patients.
  • - The treatment led to notable improvements in asthma control and sinonasal symptoms for patients with chronic rhinosinusitis with nasal polyposis, with 84.31% achieving partial or complete clinical remission.
  • - Results indicate benralizumab may act as a long-term disease-modifying drug for SEA, with most patients able to reduce or stop their oral corticosteroids, but further research is needed to evaluate its long-term safety and effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • Normal-weight individuals with asthma often engage in less physical activity, and this study aimed to assess the impact of a pulmonary rehabilitation program on their daily activity levels.
  • The feasibility study involved 17 participants wearing accelerometers to measure their steps and activity time before and after the program, with usable data from 16 participants ultimately analyzed.
  • Results showed a modest increase in daily steps and a slight decrease in activity time post-rehabilitation, while also noting improvements in quality of life, muscle strength, and exercise capacity.
View Article and Find Full Text PDF
Article Synopsis
  • High blood eosinophils in COPD patients may indicate how well they respond to inhaled corticosteroids (ICS) treatment, but this study focused on those treated only with bronchodilators for two years.
  • The study monitored 63 COPD patients' lung function, blood and sputum eosinophils, and exacerbations every six months, finding that after two years, 29% of patients needed to add ICS due to worsening symptoms.
  • Despite some patients receiving ICS, blood and sputum eosinophil levels remained stable and did not correlate with exacerbations, though a history of ischemic heart disease was linked to increased blood eosinophils over time.
View Article and Find Full Text PDF

INTRODUCTIONAlpha-1 antitrypsin (AAT) deficiency, an autosomal co-dominant condition, decreases protein concentration and activity at both serum and tissue levels. Few studies investigated whether the type of gene phenotype in patients with severe asthma can influence symptoms and disease control during follow-up.OBJECTIVETo assess whether the presence of a non-MM genotype of in patients with severe asthma is associated with disease control, systemic and airway inflammation, lung function and comorbidities prevalence compared to severe asthma patients with a homozygous genotype (MM).

View Article and Find Full Text PDF

Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP.

View Article and Find Full Text PDF

Historically, all efforts against tuberculosis were focused on rapid diagnosis and effective treatment to break the chain of transmission of Mycobacterium tuberculosis. However, in the last few years, more and more evidence has been found on the dramatic consequences of the condition defined as post-tuberculosis lung disease (PTLD). Approximately one third of patients surviving pulmonary tuberculosis face considerable ongoing morbidities, including respiratory impairment, psychosocial challenges, and reduced health-related quality of life after treatment completion.

View Article and Find Full Text PDF

(1) Background: "Brittle Asthma" was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases.

View Article and Find Full Text PDF
Article Synopsis
  • This global study investigates the long-term outcomes of patients with tuberculosis (TB) and COVID-19, highlighting a lack of prior longitudinal data on this combined condition.
  • Data was collected from 788 patients across 31 countries from March 2020 to September 2022, showing a mortality rate of 10.8% during the study period.
  • Key factors influencing mortality included older age, HIV infection, and the need for invasive ventilation, with patients suffering from both diseases experiencing significantly lower survival rates compared to those with only one of the diseases.
View Article and Find Full Text PDF
Article Synopsis
  • - The clinical standards aim to establish best practices for diagnosing, treating, and preventing post-COVID-19 lung disease, developed by a panel of 45 international experts using a consensus process.
  • - Four key standards were set for evaluating patients with a history of COVID-19, focusing on identifying lung disease, offering rehabilitation for ongoing symptoms, customizing treatment programs, and assessing the effectiveness of rehabilitation efforts.
  • - This initiative represents the first consensus-based framework to enhance patient care and quality of life by providing clear guidance for healthcare professionals and public health officials on managing post-COVID-19 lung disease.
View Article and Find Full Text PDF

Background: Few data are available on the effects of pulmonary rehabilitation (PR) on risk of fall in over 80 individuals with chronic obstructive pulmonary disease (COPD). We investigated the effectiveness of PR on the risk of fall in older as compared to younger than 80 individuals.

Methods: Parallel-group retrospective exploratory study of individuals undergone in-hospital PR.

View Article and Find Full Text PDF

The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs). A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards. Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.

View Article and Find Full Text PDF

Introduction: Patients with severe COVID-19 often experience long-lasting disabilities that can improve after pulmonary rehabilitation. Moreover patients with severe COVID-19 display thyroid function alterations due to a non-thyroidal illness syndrome (NTIS). The aim of our study was to evaluate thyroid function parameters among patients hospitalized for COVID-19 who were eligible or not to respiratory rehabilitation and their modifications during follow-up.

View Article and Find Full Text PDF

We performed an analysis of the cost and relative merits of different strategies for the diagnosis of multidrug-resistant/extensively drug-resistant TB (MDR/XDR-TB) in different settings. We systematically reviewed the published evidence on cost/cost-effectiveness of rapid MDR/pre-XDR-TB and other methods for XDR-TB testing up to September 2022. PRISMA guidelines were followed.

View Article and Find Full Text PDF

Background: Patients with asthma usually present airway inflammation classified as eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic pattern according to sputum inflammatory cells.

Objective: The aim of the study was to analyze clinical and biological characteristics of patients with asthma and mixed granulocytic pattern in comparison with the other groups.

Methods: Induced sputum was used to assess airway inflammation; lung function was evaluated as well as blood leukocytes and disease control.

View Article and Find Full Text PDF

Heart rate recovery (HRR) after exercise is a marker of disease severity and prognosis in cardiovascular and respiratory disorders. More than 30% of adult individuals with asthma may show a slow HRR. Pulmonary rehabilitation improves exercise capacity in individuals with asthma or chronic obstructive pulmonary disease (COPD).

View Article and Find Full Text PDF

Severe asthma patients' life is heavily influenced by the disease, which has impact on personal and professional choices or general lifestyle. Despite the available tools to help physicians investigating the patient-reported outcomes there is a need for a more standardised and structured approach to include the evaluation of quality of life together with the emotions of patients into the routine clinical interaction. We hereby report the use of an active listening and insight approach to understand the emotions of patients with severe asthma through dedicated in-person meetings involving a group of patients with their doctors, caregivers and an external moderator.

View Article and Find Full Text PDF

Objective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test (SNOT)-22 score, Nasal Polyp (NP) score, and blood eosinophil count during a 12-month treatment with mepolizumab.

View Article and Find Full Text PDF

Introduction: There is a global unmet need for rehabilitation to meet which the World Health Organization, in collaboration with Cochrane Rehabilitation, is developing the Package of Interventions for Rehabilitation with the aim of identifying rehabilitation interventions relevant to a range of key health conditions, including chronic obstructive pulmonary disease (COPD). The purpose of this paper is to describe the best available evidence on pulmonary rehabilitation interventions for people with COPD.

Evidence Acquisition: An Overview of Cochrane Systematic Reviews (CSRs).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess lung function in Brazilian patients with a history of pulmonary tuberculosis and compare it with similar groups from Mexico and Italy.
  • Key findings revealed distinct differences in pulmonary function across the cohorts, with the Brazilian group showing a greater decline in lung function post-treatment.
  • The conclusions emphasize the necessity for prompt and effective treatment of drug-susceptible tuberculosis to minimize lung damage and recommend early evaluations and rehabilitation for those with post-tuberculosis lung disease.
View Article and Find Full Text PDF